Composition for preventing or treating hair loss comprising tubulin inhibitor

Abstract

The present invention relates to a composition for inhibiting hair loss, promoting new hair growth, or promoting hair growth, comprising a tubulin inhibitor as an active ingredient. Also, the present invention relates to a pharmaceutical composition for inhibiting hair loss, promoting new hair growth, or promoting hair growth, comprising a tubulin inhibitor as an active ingredient. Also, the present invention relates to a quasi-drug composition for inhibiting hair loss, promoting new hair growth, or promoting hair growth, comprising a tubulin inhibitor as an active ingredient. Also, the present invention relates to a cosmetic composition for inhibiting hair loss, promoting new hair growth, promoting hair growth, and alleviating symptoms of hair loss, comprising a tubulin inhibitor as an active ingredient. Also, the present invention relates to a hair or scalp product comprising a tubulin inhibitor as an active ingredient. When the tubulin inhibitor of the present invention was applied to an animal model, the animal model was confirmed to exhibit significantly increased new hair growth, hair loss inhibition, and hair growth promotion effects, compared to a control. Therefore, the tubulin inhibitor of the present invention can be effectively used as a medicine or cosmetic product for hair loss or hair growth.

Description

Composition for preventing or treating hair loss comprising a tubulin inhibitor

[0001] The present invention relates to a composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, which comprises a tubulin inhibitor as an active ingredient.

[0002] In addition, the present invention relates to a pharmaceutical composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, which comprises a tubulin inhibitor as an active ingredient.

[0003] In addition, the present invention relates to a pharmaceutical composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, which comprises a tubulin inhibitor as an active ingredient.

[0004] In addition, the present invention relates to a cosmetic composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, which comprises a tubulin inhibitor as an active ingredient.

[0005] In addition, the present invention relates to a product for hair or scalp, comprising a tubulin inhibitor as an active ingredient.

[0006] Human hair primarily serves a defensive function, protecting the scalp from external irritants like UV rays, and also plays an aesthetic role in expressing an individual's external image. However, in modern society, hair loss is becoming more common due to natural factors like environmental pollution and strong UV rays, as well as physiological factors like stress and hormonal imbalances. Unlike in the past, when hair loss was limited to adult men, hair loss is now affecting people of all ages and genders, creating a pressing need for preventative and therapeutic solutions.

[0007] Hair follicles, physiological organs in the body that produce hair, are involved in the growth, maintenance, and loss of hair by repeating the hair growth cycle, which is divided into the anagen phase, in which hair is produced and actively grows, the catagen phase, in which hair degenerates, the telogen phase, in which hair falls out, and the exogen phase, in which hair loss occurs. Many studies have revealed that the activity of these hair follicles is caused by hair dermal papilla cells, and in particular, the proliferation and differentiation of dermal papilla cells are primarily involved in the progression of the hair growth cycle and hair formation. During the anagen phase, when hair actively grows, dermal papilla cells actively proliferate and differentiate, and during the catagen phase, when hair growth stops and hair loss occurs, these cells die. Therefore, since hair growth and hair loss are closely related to the proliferation and death of hair papilla cells, inducing their proliferation to prolong the growth phase or suppressing cell death to shorten the regression phase, resting phase, and hair loss phase will be a way to improve and treat hair loss.

[0008] Alopecia is a condition in which more than 100 hairs fall out per day, the number of hairs in the growth phase decreases, and the number of hairs in the catagen or telogen phase increases. As hair loss progresses, the proportion of hairs in the telogen phase increases rapidly, and the proportion of hairs in the growth phase decreases correspondingly. Hair loss can generally be categorized as hereditary androgenetic alopecia (baldness), alopecia areata, tinea capitis caused by a fungal infection, telogen effluvium, trichotillomania, and hair growth disorders. The most common types of hair loss include alopecia (male pattern baldness), female pattern baldness, alopecia areata, and telogen effluvium. The causes of hair loss are diverse. Genetic factors and androgens, a male hormone, are considered important factors in the development of baldness. It is believed that some types of female pattern baldness occur through the same pathway as androgenetic alopecia, but there are clinical differences in their manifestations. Alopecia areata is thought to be caused by an autoimmune disease. Telogen effluvium is a temporary hair loss that occurs after severe physical or mental stress such as endocrine diseases, nutritional deficiencies, medications, childbirth, fever, and surgery. It occurs when some hairs do not complete the growth period and transition to the resting phase, falling out.

[0009] Accordingly, the inventors of the present invention confirmed that a tubulin inhibitor has an effect of inhibiting hair loss, promoting hair growth, or promoting hair growth, and completed the present invention.

[0010] Accordingly, an object of the present invention is to provide a composition for inhibiting hair loss, promoting hair growth, or promoting hair growth.

[0011] In addition, it is an object of the present invention to provide a pharmaceutical, quasi-drug, or cosmetic composition for inhibiting hair loss, promoting hair growth, or promoting hair growth.

[0012] It is also an object of the present invention to provide a product for hair or scalp.

[0013] To achieve the above purpose, the present invention provides a composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, containing a tubulin inhibitor as an active ingredient.

[0014] In addition, the present invention provides a pharmaceutical composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, which comprises a tubulin inhibitor as an active ingredient.

[0015] In addition, the present invention provides a pharmaceutical composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, which contains a tubulin inhibitor as an active ingredient.

[0016] In addition, the present invention provides a cosmetic composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, which contains a tubulin inhibitor as an active ingredient.

[0017] In addition, the present invention provides a product for hair or scalp containing a tubulin inhibitor as an active ingredient.

[0018] In addition, the present invention provides a method for suppressing hair loss, promoting hair growth, promoting hair growth, or alleviating hair loss symptoms, comprising a step of administering a tubulin inhibitor to a subject in need thereof.

[0019] The tubulin inhibitors of the present invention, particularly ABT-751, TN-16, Plinabuline, and Combretastatin A4, were tested in animal models, and significantly increased hair growth, hair loss inhibition, and hair growth promotion effects were observed compared to the control group. Accordingly, the tubulin inhibitors of the present invention can be effectively used as hair loss or hair growth drugs or cosmetics.

[0020] Figure 1 is a photograph showing the results of observing the hair growth effect when a tubulin inhibitor was applied to an animal model (hos:HR-1 mouse). Figure 1 shows that the hair growth effect was significantly increased in mice treated with the tubulin inhibitors ABT-751, TN-16, Plinabuline, and Combretastatin A4 compared to the control group that did not contain the compound.

[0021] Figure 2 is a graph showing the results of quantitatively measuring the number of hairs per unit area (hair density) after application of a tubulin inhibitor. The graph in Figure 2 shows that hair density significantly increased in the group to which the tubulin inhibitor was applied compared to the control group.

[0022]

[0023] Hereinafter, the present invention will be described in detail.

[0024]

[0025] The present invention provides a composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, which comprises a tubulin inhibitor as an active ingredient.

[0026] The present invention also provides a method for suppressing hair loss, promoting hair growth, promoting hair growth, or alleviating hair loss symptoms, comprising a step of administering a tubulin inhibitor to a subject in need thereof.

[0027] Tubulin inhibitors (Tubulin inhibitors) refer to a group of drugs that regulate or inhibit the function of tubulin, a key component of microtubules. Microtubules are part of the cytoskeleton, playing a crucial role within cells and are essential structures for processes such as cell division, cell movement, and intracellular transport.

[0028] In the present invention, the tubulin inhibitor, unlike its previous function, exhibited hair growth efficacy in an animal model.

[0029] In the present invention, the tubulin inhibitor is not limited in type, but may be, for example, ABT-751, TN16, Combretastatin-A4, or Plinabuline.

[0030] The above ABT-751 may be represented by the following compound I.

[0031] [Chemicals I]

[0032]

[0033] The above compound I is a compound with CAS registry number 141430-65-1, ABT-751 (N-[2-[(4-Hydroxyphenyl)amino]pyridin-3-yl]-4-methoxybenzenesulfonamide).

[0034] ABT-751 is a compound that targets microtubules, and the drug has been reported to exhibit activity in stopping the growth of cancer cells by inhibiting cell division in certain cancer cells.

[0035] The above TN16 can be represented by the following compound II.

[0036] [Chemicals II]

[0037]

[0038] In addition, the compound II is a compound with CAS registry number 33016-12-5, TN-16 (3-[1-(phenylamino)ethylidene]-5-(phenylmethyl)-2,4-pyrrolidinedione).

[0039] TN-16 is a novel microtubule inhibitor with antitumor activity. It was synthesized by modifying tenuazonic acid (3-acetyl-5-sec-butyltetramic acid), a natural antibiotic isolated and characterized from cultures of Alternaria tenuis. In 1967, TN-16 was discovered to possess potent anticancer properties, but subsequent studies failed to identify a more potent agent. Furthermore, in 1983, the mechanism of action of TN-16 was revealed to be inhibition of microtubule formation, acting by binding to a sensitive site.

[0040] In the present invention, Combretastatin-A4 binds to tubulin, inhibits polymerization of microtubules, destroys the cytoskeleton within cancer cells, induces cell death, and is known to exhibit an anti-angiogenic effect as a candidate for an anticancer agent.

[0041] In addition, in the present invention, plinabulin acts as a tubulin inhibitor and an anti-angiogenic agent, and is known to inhibit the growth of cancer tissue by simultaneously targeting cancer cells and blood vessels.

[0042] The tubulin inhibitor of the present invention is a concept that includes all pharmaceutically acceptable salts, isomers, derivatives, and analogs that exhibit the same or similar effects.

[0043] In the present invention, pharmaceutically acceptable salts refer to salts commonly used in the pharmaceutical industry, and examples thereof include inorganic ion salts manufactured with calcium, potassium, sodium and magnesium, inorganic acid salts manufactured with hydrochloric acid, nitric acid, phosphoric acid, hydrobromic acid, iodic acid, perchloric acid and sulfuric acid, organic acid salts manufactured with acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid and hydroiodic acid, sulfonic acid salts manufactured with methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and naphthalenesulfonic acid, glycine, Examples thereof include, but are not limited to, amino acid salts manufactured from arginine, lysine, etc., and amine salts manufactured from trimethylamine, triethylamine, ammonia, pyridine, picoline, etc.

[0044] The above tubulin inhibitor may be derived from an extract, produced biologically, or synthesized chemically, and is not limited in its origin and production method.

[0045]

[0046] The tubulin inhibitor of the present invention can be used for suppressing hair loss, promoting hair growth, or promoting hair growth.

[0047] The term “hair loss” used in the present invention means the absence of hair in an area where hair should normally be present, and includes a phenomenon in which the number of hairs decreases compared to the normal state. The above hair loss is a concept that includes both non-scarring hair loss and scarring hair loss depending on whether hair follicles are destroyed, and includes, for example, hereditary androgenetic alopecia, alopecia areata, tinea capitis caused by fungal infection, telogen effluvium, trichotillomania, hair growth disorder, hair loss due to lupus, folliculitis fulminans, lichen planus pilaris, hair loss due to burns and / or trauma, etc.

[0048] The term “hair loss inhibition” used in the present invention means preventing or slowing down the abnormal loss of existing hair.

[0049] The term “hair growth” used in the present invention refers to the process in which new hair grows as a hair follicle in the resting phase (telogen) transitions to the growth phase (anagen).

[0050] The term “hair growth promotion” as used in the present invention means inducing or activating the process of new hair growth.

[0051] The term “promoting hair growth” as used in the present invention means increasing the length and thickness of hair that is already growing, or accelerating the growth rate.

[0052] In the present invention, the tubulin inhibitor may be provided as an active ingredient in a pharmaceutical composition for inhibiting hair loss, promoting hair growth, or promoting hair growth. Furthermore, it may be used as a pharmaceutical composition for preventing or treating hair loss.

[0053] The term “prevention” as used herein may include inhibiting the occurrence of a disease.

[0054] The term “treatment” as used herein includes inhibition, alleviation, or elimination of the development of a disease.

[0055] The term "included as an active ingredient" in this specification means that the tubulin inhibitor of this specification is added to an extent that it can exhibit the effect mentioned in this specification, and includes the formulation in various forms by adding various components as auxiliary components for drug delivery and stabilization, etc.

[0056] The pharmaceutical composition may contain the tubulin inhibitor in a pharmaceutically effective amount.

[0057] As used herein, the term “pharmaceutically effective amount” means an amount sufficient to achieve the efficacy or activity of an active ingredient.

[0058] The pharmaceutical composition may additionally comprise a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, mannitol, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a glidant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium hydrogen phosphate anhydrous, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The glidant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

[0059] The above pharmaceutical composition may be formulated as an oral or parenteral dosage form. Oral dosage forms may include granules, powders, liquids, tablets, capsules, dry syrups, or combinations thereof. Parenteral dosage forms may include injections, ointments, aerosols, sprays, patches, and the like, with no particular limitation on the dosage form.

[0060] The dosage of the pharmaceutical composition according to one example is, for example, about 0.0001 to 10000 mg / kg, 0.0001 to 5000 mg / kg, 0.0001 to 1000 mg / kg, 0.0001 to 900 mg / kg, 0.0001 to 800 mg / kg, 0.0001 to 700 mg / kg, 0.0001 to 600 mg / kg, 0.0001 to 500 mg / kg, 0.0001 to 400 mg / kg, 0.0001 to 300 mg / kg, 0.0001 to 200mg / kg, 1 to 1000mg / kg, 1 to 900mg / kg, 1 to 800mg / kg, 1 to 700mg / kg, 1 to 600mg / kg, 1 to 500mg / kg, 1 to 450mg / kg, 1 to 400mg / kg, 1 to 350mg / kg, 1 to 300mg / kg, 1 to 250mg / kg, 10 to 1000mg / kg, 10 to 900mg / kg, 10 to 800mg / kg, 10 to 700mg / kg, 10 to 600mg / kg, 10 to 500mg / kg, 10 to 450mg / kg, 10 to 400mg / kg, 10 to 350mg / kg, 10 to 300mg / kg, 10 to 250mg / kg, 100 to 1000mg / kg, 100 to 900mg / kg, 100 to 800mg / kg, 100 to 700mg / kg, 100 to 600mg / kg, 100 to 500mg / kg, 100 to 450mg / kg, 100 to 400mg / kg, 100 to 350mg / kg, 100 to 300mg / kg, 100 to 250mg / kg, 200 to 1000mg / kg, 200 to 900mg / kg, 200 to 800mg / kg, 200 to 700mg / kg, 200 to 600mg / kg, 200 The dosage may be administered in the range of 500 mg / kg to 500 mg / kg, 200 to 450 mg / kg, 200 to 400 mg / kg, 200 to 350 mg / kg, 200 to 300 mg / kg, or 200 to 250 mg / kg, but is not limited thereto. The frequency of administration of the pharmaceutical composition of the present application is not particularly limited thereto, but may be administered once a day or administered in divided doses several times. The above dosage does not limit the scope of the present application in any way.

[0061]

[0062] The subject of administration of the pharmaceutical composition provided herein may be a mammal including a human, a dog, a cat, a horse, a cow, a pig, a goat, a rabbit, a mouse, a rat, etc., or a cell, tissue, or culture thereof isolated therefrom. In one example, the subject may be a subject (a mammal such as a human) that requires prevention, improvement, and / or treatment of a skin disease as described above, or a cell, tissue, or culture thereof isolated therefrom.

[0063] According to an example, a pharmaceutical composition comprises the tubulin inhibitor in an amount of 1 to 80 wt%, 5 to 80 wt%, 5 to 75 wt%, 5 to 70 wt%, 5 to 65 wt%, 50 to 70 wt%, 55 to 65 wt%, 60 to 65 wt%, 10 to 60 wt%, 15 to 60 wt%, 20 to 60 wt%, 1 to 50 wt%, 5 to 50 wt%, 10 to 50 wt%, 15 to 50 wt%, 20 to 50 wt%, 1 to 40 wt%, 5 to 40 wt%, 10 to 40 wt%, 15 to 40 wt%, 20 to 40 wt%, 1 to 30 wt%, 5 to 30 wt%, 10 to It may comprise 30 wt%, 15 to 30 wt%, 20 to 30 wt%, 1 to 25 wt%, 5 to 25 wt%, 10 to 25 wt%, 15 to 25 wt%, 20 to 25 wt%, or 23 to 25 wt%.

[0064]

[0065] Alternatively, the composition may be a composition for external use in the skin.

[0066] The above skin external preparation may be, but is not limited to, a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, spray, or a combination thereof.

[0067] In the present invention, the external skin preparation may be appropriately mixed with ingredients commonly used in external skin preparations such as cosmetics or medicines, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, metal ion sequestrants, sugars, or combinations thereof, as needed.

[0068]

[0069] Additionally, the present invention provides a quasi-drug composition for suppressing hair loss, promoting hair growth, or promoting hair growth, comprising a tubulin inhibitor as an active ingredient. Furthermore, the composition can be used as a quasi-drug composition for preventing or treating hair loss.

[0070] In the present invention, a quasi-drug refers to any product other than a drug related to the treatment or prevention of a disease.

[0071] In the present invention, quasi-drugs refer to all products other than pharmaceuticals related to the treatment or prevention of diseases. The quasi-drugs above refer to products that are used for the purpose of diagnosing, treating, improving, alleviating, managing, or preventing diseases of humans or animals, and have a milder effect than pharmaceuticals. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are products excluding those used for the purpose of pharmaceuticals, and may include, but are not limited to, fiber and rubber products used for the treatment or prevention of diseases of humans or animals, products that have a mild or no direct effect on the human body, are not instruments or machines, and similar products, and sterilizers and insecticides for preventing infectious diseases.

[0072] The type or formulation of the pharmaceutical composition of the present invention is not particularly limited, but may preferably be a disinfectant, a shower foam, a gargle, a wet tissue, a detergent soap, a hand wash, a humidifier filler, a mask, an ointment, or a filter filler.

[0073] When the composition of the present invention is included in a quasi-drug, the composition may be used as is or in combination with other quasi-drug ingredients, and may be used appropriately according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the intended use, and the quasi-drug composition according to the present invention may contain the tubulin inhibitor in an amount of 0.01 to 20 wt% based on the total weight of the composition.

[0074] Furthermore, the present invention provides a cosmetic composition for inhibiting hair loss, promoting hair growth, or alleviating hair loss symptoms in skin diseases, comprising a tubulin inhibitor as an active ingredient. Furthermore, the cosmetic composition can be used for preventing or treating hair loss.

[0075] The term "improvement" herein may mean any action that at least reduces the severity of a symptom, for example, a parameter associated with alleviating or treating a condition.

[0076] The tubulin inhibitor is present in an amount of 0.0001 to 80 wt%, 0.01 to 70 wt%, 0.01 to 60 wt%, 0.01 to 50 wt%, 0.01 to 40 wt%, 0.01 to 30 wt%, 0.1 to 70 wt%, 0.1 to 60 wt%, 0.1 to 50 wt%, 0.1 to 40 wt%, 0.1 to 30 wt%, 0.5 to 70 wt%, 0.5 to 60 wt%, 0.5 to 50 wt%, 0.5 to 40 wt%, 0.5 to 30 wt%, 1 to 70 wt%, 1 to 60 wt%, 1 to 50 wt%, 1 to 40 wt%, or 1 to 30%, based on the total weight of the cosmetic composition. For example, it may be included at 30 wt%, but is not limited thereto.

[0077] The above cosmetic composition is not particularly limited to a specific formulation, and the formulation may be appropriately selected depending on the intended purpose. The cosmetic composition may, for example, have a solubilized formulation, an emulsified formulation, or a dispersed formulation. The cosmetic composition may have a cosmetic formulation of an emollient toner, a nourishing toner, a massage cream, a nourishing cream, an essence, a pack, a gel, an ampoule, or a skin-adhesive type, but is not limited thereto.

[0078] The above cosmetic composition may additionally include ingredients commonly used in cosmetic compositions in addition to the effective ingredients disclosed herein, and may include, for example, conventional auxiliary agents and carriers such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, preservatives, vitamins, pigments, and fragrances.

[0079]

[0080] In addition, the present invention provides a hair or scalp product comprising a tubulin inhibitor as an active ingredient.

[0081] The above product may be at least one selected from the group consisting of hair growth agents, scalp cleansing agents, scalp scaling agents, scalp massage agents, scalp care agents, detergents, shampoos, tonics, hair conditioners, hair lotions, gels, packs, creams, essences, powders, sprays, oils, soaps, ointments, hair styling agents, hair dyes, and perms.

[0082]

[0083] Another aspect of the present invention provides a method for inhibiting hair loss, promoting hair growth, or preventing, improving, or treating hair loss, comprising administering an effective amount of the tubulin inhibitor to a subject in need thereof.

[0084] The term "effective amount" means an amount effective enough to produce the effect mentioned above.

[0085] The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat. The subject may be an object in need of a preventive, ameliorating, or therapeutic effect for a skin disease.

[0086] As used herein, the term "administering" is used interchangeably with "introducing" and "implanting" and may mean placement of a composition according to one embodiment into a subject by a method or route that results in at least partial localization of the composition to a desired site.

[0087] Administration may be by any method known in the art. The route of administration, frequency of administration, and other administration methods can be appropriately selected by those skilled in the art. Administration may be administered directly to a subject by any means, including intravenous, intramuscular, oral, transdermal, mucosal, intranasal, buccal, intratracheal, or subcutaneous administration. Administration may be systemic or local. Administration may include application to the skin.

[0088] In the present invention, administration is 0.1 mg to 1,000 mg of the composition according to one specific example per subject per day, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg The dosage may be administered in the range of 100 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg. However, the dosage may be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a person skilled in the art can appropriately adjust the dosage by considering these factors. The number of administrations may be once a day or twice or more within the range of clinically acceptable side effects, and the administration site may be administered in one or more sites, and the total number of administration days may be from 1 to 30 days per treatment at intervals of 2 to 5 days daily or every day. If necessary, the same treatment may be repeated after an appropriate period. For animals other than humans, the same dosage per kg as for humans may be administered, or the dosage may be converted to the above dosage based on the volume ratio (e.g., average value) of the organs (heart, etc.) of the target animal and humans.

[0089] Another aspect provides the use of the tubulin inhibitor for preparing a composition for inhibiting hair loss, promoting hair growth or promoting hair growth.

[0090] Another aspect provides the use of the tubulin inhibitor for use in the manufacture of a drug for inhibiting hair loss, promoting hair growth or promoting hair growth.

[0091] Another aspect provides a food composition for inhibiting hair loss, promoting hair growth, or promoting hair growth, comprising the tubulin inhibitor of the present invention as an active ingredient.

[0092] A food composition according to one embodiment of the present invention may be in the form of a liquid or solid formulation, and may be in the form of a tablet, capsule, soft capsule, pill, granule, beverage (drink), diet bar, chocolate, caramel formulation, or confectionery formulation, and the formulation is not particularly limited. In addition to the above-mentioned effective ingredient, the food composition of the present invention may contain excipients, sugars, flavorings, colorings, fats, proteins, etc. as needed.

[0093]

[0094] Duplicate contents are omitted in consideration of the complexity of this specification, and terms not otherwise defined in this specification have meanings commonly used in the technical field to which the present invention belongs.

[0095] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are only illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[0096] [Example 1] Confirmation of hair growth efficacy in an animal model by a tubulin inhibitor.

[0097] To investigate the efficacy of tubulin inhibitors in promoting hair growth, hos:HR-1 (hairless) mice were used as experimental animals. Because this animal model lacks hair, it offers the advantage of allowing direct application of drugs to the skin or inducing skin diseases with chemical or biological allergens, enabling skin-related research. Furthermore, at 8-10 weeks of age, the skin thickness of these mice is approximately 0.4 mm, similar to human skin, making them useful for studying the pathogenesis of skin diseases and identifying biochemical changes within skin tissue.

[0098] The same amount of 2% formulation of ABT-751 or 2% formulation of TN-16 was applied to the dorsal skin of hos:HR-1 (hairless) mice (hereinafter referred to as HR-1 mice) once a day for two weeks.

[0099] After each application, the degree of hair growth was measured. The results in Figure 1 are photographed 14 days later.

[0100] As can be seen in Fig. 1, compared to the control group that did not contain any compound, the hair growth effect was significantly increased in mice treated with tubulin inhibitors ABT-751, TN-16, Plinabuline, or Combretastatin A4.

[0101]

[0102] [Example 2] Hair growth efficacy in an animal model by application

[0103] To quantitatively confirm the hair growth efficacy of tubulin inhibitors, hair density was measured. Hair density was calculated based on the number of hairs per unit area. To measure hair density, images taken with a microscope at the original magnification of X400 were used. Data were collected by analyzing the captured images and directly counting the number of hairs within the corresponding area. Based on the hair counts obtained in this way, a graph was created to visually represent the results, which is shown in Figure 2.

[0104] As can be seen in Fig. 2, compared to the control group that did not contain any compound, significant hair growth was observed in mice treated with tubulin inhibitors ABT-751, TN-16, Plinabuline, or Combretastatin A4.

Claims

1. A composition for suppressing hair loss, promoting hair growth or promoting hair growth, containing a tubulin inhibitor as an active ingredient.

2. A composition according to claim 2, wherein the tubulin inhibitor is at least one selected from the group consisting of ABT-751, TN16, Combretastatin-A4, and Plinabuline.

3. A pharmaceutical composition for suppressing hair loss, promoting hair growth or promoting hair growth, containing a tubulin inhibitor as an active ingredient.

4. A pharmaceutical composition for suppressing hair loss, promoting hair growth or promoting hair growth, containing a tubulin inhibitor as an active ingredient.

5. A cosmetic composition for suppressing hair loss, promoting hair growth, promoting hair growth or alleviating hair loss symptoms, containing a tubulin inhibitor as an active ingredient.

6. A product for hair or scalp containing a tubulin inhibitor as an active ingredient.

7. In claim 6, the product is a hair or scalp product, wherein the product is at least one selected from the group consisting of hair tonics, scalp cleansing agents, scalp scaling agents, scalp massage agents, scalp care agents, detergents, shampoos, tonics, hair conditioners, hair lotions, gels, packs, creams, essences, powders, sprays, oils, soaps, ointments, hair styling agents, hair dyes, and perms.

8. A method for suppressing hair loss, promoting hair growth, promoting hair growth, or alleviating hair loss symptoms, comprising a step of administering a tubulin inhibitor to a subject in need thereof.

Images